This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center of the U.S. Department of Veterans Affairs (VA) to Urogen Pharma Inc., a pharmaceutical company specializing in the drug JELMYTO. The single-award BPA, valued at up to $2.5 million, was made under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and is valid through February 2026.
The purpose of this BPA is to provide the VA with a streamlined procurement vehicle to order JELMYTO, a drug used to treat low-grade upper tract urothelial cancer in veterans. Urogen Pharma Inc. has received multiple delivery orders under this BPA, as well as other VA contracts and IDVs, to supply JELMYTO to various Veterans Integrated Service Networks (VISNs) across the country. These awards have been made on a full and open competition basis, without any set-aside designations. The BPA and associated delivery orders support the VA's efforts to efficiently procure JELMYTO to address the needs of veterans suffering from this specific type of cancer.
Generated 1/17/25, 9:05 AM